Create Your Account for Free
Get your email verified and your free account activated
DASS-167, also known as 2-{[4-(4-aminopiperidin-1-yl)-3-bromophenyl]amino}-5-chlorobenzonitrile, is a small molecule inhibitor that has been designed to target the SARS-CoV-2 virus. The compound was first identified through a high-throughput screening campaign, which involved testing a large library of compounds against the viral enzyme, main protease (Mpro). Mpro is a crucial enzyme for the replication of the SARS-CoV-2 virus, and inhibiting its activity has been a key strategy for the development of COVID-19 therapeutics.
The COVID-19 pandemic, caused by the SARS-CoV-2 virus, has had a profound impact on global health and economies. Despite the development of vaccines and various treatments, the ongoing evolution of the virus has led to a continued search for effective therapeutic agents. Recently, researchers have identified a promising new compound, DASS-167, which has shown potent inhibitory activity against the SARS-CoV-2 virus. In this article, we will explore the DASS-167 compound, its mechanism of action, and its potential as a therapeutic agent against COVID-19. DASS-167
The DASS is a self-report questionnaire developed by Syd Lovibond and Peter Lovibond in 1995. The original DASS consists of 42 items, divided into three subscales: The COVID-19 pandemic, caused by the SARS-CoV-2 virus,
Create Your Account for Free
Get your email verified and your free account activated
Find Members
Our advanced search will find you local members in just seconds
Message a User
Secure and private messaging system to keep things anonymous